E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 3/1/2010 in the Prospect News Distressed Debt Daily.

Vion Pharmaceuticals statement approved; confirmation hearing April 6

By Caroline Salls

Pittsburgh, March 1 - Vion Pharmaceuticals Inc.'s disclosure statement was approved Monday by the U.S. Bankruptcy Court for the District of Delaware.

The plan of liquidation confirmation hearing is scheduled for April 6.

Under the plan, the company's remaining assets, which consist mainly of sale proceeds, will be transferred to a liquidating trust and distributed to creditors.

Creditor treatment will include:

• Holders of administrative claims, priority tax claims and priority claims will recover 100% in cash;

• Holders of secured claims will recover 100% either in cash or through the return of the collateral securing the claim;

• Holders of general unsecured claims, including notes claims, will recover 13% to 17% through a share of distributable cash; and

• Holders of interests and interest-related claims arising from common stock will receive no distribution.

Vion, a New Haven, Conn., drug development company, filed for bankruptcy on Dec. 17. Its Chapter 11 case number is 09-14429.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.